Cover Image
市場調查報告書

Osel Inc. - 產品平台分析

Osel Inc. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 253790
出版日期 內容資訊 英文 20 Pages
訂單完成後即時交付
價格
Back to Top
Osel Inc. - 產品平台分析 Osel Inc. - Product Pipeline Review - 2014
出版日期: 2014年07月31日 內容資訊: 英文 20 Pages
簡介

Osel Inc.是藉由調節微生物叢,開發治療及預防婦產科疾病和消化器官疾病、感染疾病之活生物治療產品技術性平台的生物製藥公司。

本報告提供Osel Inc.的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Osel Inc.的基本資料

Osel Inc.概要

  • 主要資訊
  • 企業資料

Osel Inc.:R&D概要

  • 主要的治療範圍

Osel Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Osel Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

Osel Inc.:藥物簡介

  • LACTIN-V
  • MIYA-BM
  • Cyanovirin-N

Osel Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Osel Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC05802CDB

Summary

Global Markets Direct's, 'Osel Inc. - Product Pipeline Review - 2014', provides an overview of the Osel Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Osel Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Osel Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Osel Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Osel Inc.'s pipeline products

Reasons to buy

  • Evaluate Osel Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Osel Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Osel Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Osel Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Osel Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Osel Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Osel Inc. Snapshot
    • Osel Inc. Overview
    • Key Information
    • Key Facts
  • Osel Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Osel Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Osel Inc. - Pipeline Products Glance
    • Osel Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Osel Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Osel Inc. - Drug Profiles
    • LACTIN-V
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MIYA-BM
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cyanovirin-N
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Osel Inc. - Pipeline Analysis
    • Osel Inc. - Pipeline Products by Target
    • Osel Inc. - Pipeline Products by Route of Administration
    • Osel Inc. - Pipeline Products by Molecule Type
    • Osel Inc. - Pipeline Products by Mechanism of Action
  • Osel Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Osel Inc., Key Information
  • Osel Inc., Key Facts
  • Osel Inc. - Pipeline by Indication, 2014
  • Osel Inc. - Pipeline by Stage of Development, 2014
  • Osel Inc. - Monotherapy Products in Pipeline, 2014
  • Osel Inc. - Phase II, 2014
  • Osel Inc. - Preclinical, 2014
  • Osel Inc. - Pipeline by Target, 2014
  • Osel Inc. - Pipeline by Route of Administration, 2014
  • Osel Inc. - Pipeline by Molecule Type, 2014
  • Osel Inc. - Pipeline Products by Mechanism of Action, 2014

List of Figures

  • Osel Inc. - Pipeline by Top 10 Indication, 2014
  • Osel Inc. - Pipeline by Stage of Development, 2014
  • Osel Inc. - Monotherapy Products in Pipeline, 2014
  • Osel Inc. - Pipeline by Top 10 Target, 2014
  • Osel Inc. - Pipeline by Top 10 Route of Administration, 2014
  • Osel Inc. - Pipeline by Top 10 Molecule Type, 2014
  • Osel Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top